Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

3 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 3(2)

Phase 2(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07184827Phase 3Recruiting

Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women

Role: lead

NCT05930093Not ApplicableRecruiting

Evaluate the Efficacy and Safety of LivPhcD Capsules in the NAFLD Subjects

Role: lead

NCT03812874Phase 1Recruiting

A Study of PTX-9908 Injection for Non-resectable HCC with TACE

Role: lead

NCT05823584Completed

Cell-free DNA From Junction of Hepatitis B Virus Integration in HCC Patients for Monitoring Post-resection Recurrence

Role: lead

NCT01890200Phase 3Withdrawn

The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Role: lead

NCT00556504Phase 2Completed

The Effects of Adding TCM-700C on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection

Role: lead

All 6 trials loaded